Apple Develops China-Specific AI Model With Alibaba as Apple Intelligence Launch Nears 
Anthropic Eyes $6B Decart AI Acquisition Ahead of Mega IPO 
Stripe, Advent Reportedly Pursue $53 Billion PayPal Takeover 
Google Pushes Gemini AI Overhaul as Sergey Brin Targets Model Supremacy 
Tesla Roadster Reveal Could Feature SpaceX Thrusters in August 
China Automakers Accelerate Global Expansion as Domestic Car Sales Slump 
LG, Nvidia Expand AI Partnership With Humanoid Robots, AI Factories 
Paramount Weighs CNN Sale as $110B Warner Bros. Discovery Deal Faces Antitrust Fight 
Bill Ackman’s Pershing Square Returns to Netflix With Major New Stake 
Antofagasta Shares Drop 5% as Miner Cuts 2026 Copper Production Forecast 
Bank of America to Buy Up to 49.9% Stake in Jio Credit for $1.92 Billion 
Micron Stock Upgraded to Buy as New Street Sees $2 Trillion Valuation Potential 
Alphabet Shifts AI Strategy Toward Commercial Growth, Goldman Sachs Says 
Australia’s Corporate Leaders Face Parliament Over KPMG Client Data Scandal 
Paramount Skydance Clears Regulatory Hurdles for Warner Bros. Discovery Deal 
J.P. Morgan Upgrades SanDisk, Sets $2,250 Price Target on AI NAND Growth 
SMIC Shares Rally as Q2 Profit Surges 262% on Strong Chip Demand 
Add as a preferred source on Google
BRIDGEWATER, N.J., May 08, 2017 -- Valeritas Holdings, Inc. (NASDAQ:VLRX) announced today that the Company is scheduled to present at the 18th Annual B. Riley Co. Investor Conference.
| Event: | 18th Annual B. Riley Co. Investor Conference |
| Format: | Presentation and One-on-One Meetings |
| Date: | Wednesday, May 24, 2017 |
| Time: | 1:00pm PT |
| Location: | Santa Monica, CA |
An audio webcast of the Company’s presentation will be available by visiting the investor relations section of the Valeritas website at www.valeritas.com. Replays of the presentation will be available for 90 days.
About Valeritas Holdings, Inc.
Valeritas is a commercial-stage medical technology company focused on improving health and simplifying life for people with diabetes by developing and commercializing innovative technologies. Valeritas’ flagship product, V-Go® Wearable Insulin Delivery device, is a simple, wearable, basal-bolus insulin delivery device for patients with type 2 diabetes that enables patients to administer a continuous preset basal rate of insulin over 24 hours. It also provides discreet on-demand bolus dosing at mealtimes. It is the only basal-bolus insulin delivery device on the market today specifically designed keeping in mind the needs of type 2 diabetes patients. Headquartered in Bridgewater, New Jersey, Valeritas operates its R&D functions in Shrewsbury, Massachusetts. For more information, please visit www.valeritas.com.
Investor Contacts: Nick Laudico / Robert Flamm, Ph.D. The Ruth Group 646-536-7030 / 7017 [email protected] Or The Del Mar Consulting Group, Inc. Robert B. Prag, President 858-794-9500 [email protected] Media Contact: Kirsten Thomas The Ruth Group 508-280-6592 [email protected]
